Abstract:The use of nutraceuticals with anti-inflammatory and hypolipidemic activity in the composition of foods for special dietary uses and dietary supplements is one of the effective methods of dietary therapy of alimentary obesity and related diseases. The aim was to study the effect of the combined intake of resveratrol and L-carnitine (RC) on the expression of genes responsible for the metabolism of carbohydrates, fats and inflammatory reactions in the liver and kidneys of rats in normal conditions and with diet-induced obesity. Material and methods. Male Wistar rats received for 63 days a standard balanced diet or a high-fat-high-carbohydrate diet (HFCD) with an excess of total fat (30%) and fructose (20% solution instead of drinking water), or the same diets supplemented with RC in a low (25 mg/kg body weight as resveratrol and 300 mg/kg as L-carnitine) or high (50 and 600 mg/kg body weight, respectively) doses. The expression of genes (Khk, Gck, Pklr, Acaca, Acacb, Fasn, Scd, Srebf1, Mlxipl, Ppara, Pparg, Actb, Gapdh) in liver cells was studied by the method of real-time reverse transcription polymerase chain reaction (RT-PCR). The distribution of tyrosine aminotransferase (TAT), nuclear factor erythroid 2-related factor 2 (NRF-2) and intercellular adhesion molecule type 2 (ICAM-2) in the liver and kidneys was assessed by confocal laser microscopy and immunohistochemistry. Results. Increased expression of Fasn (fatty acid synthase) in rats treated with high-fat high-carbohydrate diet (HFCD) decreased under RC intake. RC consumption caused a decrease in the number of TAT-, NRF-2- and ICAM-2-positive cells in the liver of rats treated with HFCD, but had the opposite effect in the kidneys. The consumption of RC at the low dose by rats fed HFCD caused changes in the expression profiles of the studied marker genes, indicating a possible hypolipidemic effect. However, observed increased expression of lipogenic genes in the liver and elevated level of NRF-2 and ICAM-2 in kidney against the background of consumption of RC with the standard balanced diet cannot be assessed as unambiguously positive. Conclusion. Thus, possible negative effects caused, most likely, by the interaction of nutraceuticals with various mechanisms of action should be taken into account when developing formulations of dietary supplements and foods for special dietary uses for dietary therapy of obesity.

Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33.

Resveratrol Suppresses Hepatic Fatty Acid Synthesis and Increases Fatty Acid Β-Oxidation Via the Microrna-33/Sirt6 Signaling Pathway

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation

Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.

Resveratrol Improves High-Fat Induced Nonalcoholic Fatty Liver in Rats

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Effects of Resveratrol on Lipid Metabolism in C57BL/6J Mice

(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease.

MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice.

Alleviative Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Are Associated with Up Regulation of Hepatic Low Density Lipoprotein Receptor and Scavenger Receptor Class B Type I Gene Expressions in Rats

[Liver gene expression in normal and obese rats received resveratrol and L-carnitine]

The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression

Atorvastatin and Flaxseed Effects on Biochemical Indices and Hepatic Fat of NAFLD Model in Rats

Effects Of Atherogenic Diet And Atorvastatin Treatment On Gene Expression Profiles In The C57bl/6j Mouse Liver

Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m6A RNA Methylation

Alleviation Effects of Microbial Metabolites from Resveratrol on Non-Alcoholic Fatty Liver Disease

Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease

Targeting the Gut Microbiota with Resveratrol: a Demonstration of Novel Evidence for the Management of Hepatic Steatosis.

Effects of Atorvastatin on Bile Acid Metabolism in High-Fat Diet-Fed ApoE-/- Mice

Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats